Table 2 Hazard ratios of characteristics associated with VKA initiation within 3 months following NVAF diagnosis

Size, n

135,241

18-29

0.45

0.22

0.23 (0.15 - 0.36)

30-39

0.83

0.45

0.45 (0.36 - 0.58)

40-49

2.06

1.00

1.00 (Reference)

50-59

5.01

1.73

1.68 (1.51 - 1.87)

60-69

16.81

2.73

2.55 (2.31 - 2.82)

70-74

17.43

3.29

3.05 (2.77 - 3.36)

75-79

20.29

3.51

3.28 (2.97 - 3.61)

80-84

18.06

3.31

3.12 (2.83 - 3.44)

85-89

12.09

2.76

2.66 (2.41 - 2.94)

≥90

6.97

1.60

1.57 (1.41 - 1.74)

Male

47.90

1.02

1.09 (1.07 - 1.11)

Hypertension

61.66

1.21

1.03 (1.01 - 1.05)

Myocardial infarction

20.64

0.94

0.89 (0.87 - 0.92)

Angina pectoris

20.02

0.94

0.88 (0.86 - 0.90)

Congestive heart failure

20.46

1.15

1.20 (1.18 - 1.23)

Prior stroke or TIA

8.62

1.22

1.25 (1.21 - 1.28)

Intracranial bleeding

1.00

0.56

0.55 (0.49 - 0.61)

Gastrointestinal bleeding

5.75

0.65

0.67 (0.64 - 0.70)

Other bleeding

8.84

0.85

0.85 (0.83 - 0.88)

Diabetes

25.39

1.08

0.97 (0.95 - 0.99)

Hyperlipidemia

42.47

1.18

1.00 (0.95 - 1.05)

Vascular disease

12.12

0.94

0.87 (0.84 - 0.89)

Chronic renal failure

10.70

0.89

0.87 (0.84 - 0.90)

Complications of alcohol abuse

3.61

0.61

0.78 (0.73 - 0.83)

Liver disease

2.53

0.67

0.80 (0.75 - 0.85)

Cancer

19.58

0.79

0.76 (0.75 - 0.78)

Coagulation defects

1.81

0.75

0.88 (0.82 - 0.95)

Predisposition to falls

15.44

0.75

0.80 (0.78 - 0.83)

Dementia/schizophrenia

8.81

0.55

0.65 (0.63 - 0.68)

Venous thromboembolism

5.47

1.37

1.48 (1.43 - 1.53)

COPD

26.65

0.94

0.93 (0.91 - 0.95)

ACE

35.62

1.21

1.12 (1.10 - 1.15)

ARB

21.28

1.25

1.12 (1.09 - 1.14)

CCB

41.51

1.27

1.19 (1.16 - 1.21)

Diuretics

50.08

1.25

1.09 (1.07 - 1.12)

Antidepressants

19.44

0.84

0.91 (0.89 - 0.94)

Antipsychotics

5.81

0.61

0.83 (0.79 - 0.87)

NSAIDs

36.35

1.01

1.00 (0.98 - 1.02)

Statins

38.55

1.19

1.05 (1.00 - 1.10)